BKUH (Bakhu Holdings) Debt-to-Equity: -0.80 (As of Apr. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Bakhu Holdings Debt-to-Equity?

Bakhu Holdings BKUH -97.50% Debt-to-Equity is -0.80 as of Apr. 2024.

Bakhu Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Apr. 2024 was $0.41 Mil. Bakhu Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Apr. 2024 was $7.81 Mil. Bakhu Holdings's Total Stockholders Equity for the quarter that ended in Apr. 2024 was $-10.23 Mil. Bakhu Holdings's debt to equity for the quarter that ended in Apr. 2024 was -0.80.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Bakhu Holdings's Debt-to-Equity or its related term are showing as below:

BKUH's Debt-to-Equity is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.28
* Ranked among companies with meaningful Debt-to-Equity only.

Bakhu Holdings  (OTCPK:BKUH) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Bakhu Holdings Debt-to-Equity Related Terms

Bakhu Holdings Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Bakhu Holdings's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bakhu Holdings Debt-to-Equity Chart

Bakhu Holdings Annual Data
Trend Jul08 Jul09 Jul10 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.98 -0.89 -0.78 -0.89 -0.72

Bakhu Holdings Quarterly Data
Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.76 -0.72 -0.74 -0.82 -0.80

BKUH vs ALID, BLMH, LVRLF: Debt-to-Equity Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Bakhu Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bakhu Holdings Debt-to-Equity vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bakhu Holdings's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Bakhu Holdings's Debt-to-Equity falls into.


Bakhu Holdings Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Bakhu Holdings's Debt to Equity Ratio for the fiscal year that ended in Jul. 2023 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(6.745 + 0) / -9.326
=-0.72

Bakhu Holdings's Debt to Equity Ratio for the quarter that ended in Apr. 2024 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.41 + 7.814) / -10.228
=-0.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of -0.80 mean?
Bakhu Holdings (BKUH) has a Debt-to-Equity of -0.80 as of Apr. 2024. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Bakhu Holdings and its competitors.
Is Bakhu Holdings' Debt-to-Equity too high?
Bakhu Holdings' current Debt-to-Equity is -0.80.
How does Bakhu Holdings' Debt-to-Equity compare to ALID and BLMH?
Bakhu Holdings' Debt-to-Equity of -0.80 can be compared against companies in the Drug Manufacturers industry. The industry median Debt-to-Equity is 0.28. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Bakhu Holdings and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bakhu Holdings's current Debt-to-Equity is -0.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bakhu Holdings stock overvalued right now?
Bakhu Holdings (BKUH) has a current Debt-to-Equity of -0.80. The current Debt-to-Equity is -0.80. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Bakhu Holdings (BKUH), the current Debt-to-Equity is -0.80 as of Apr. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bakhu Holdings Business Description

Address One World Trade Center, Suite 130, Long Beach, CA, USA, 90831
Bakhu Holdings Corp is a development stage company engaged in the production, manufacturing, and sale of cannabis and byproducts. The company also provides cannabis-related research, teaching and education for both medical and other purposes, and all medical uses and applications of cannabis, within the Territory.